The tumour suppressor PTEN can inhibit cell proliferation and migration as well as control cell growth, in different cell types 1 . PTEN functions predominately as a lipid phosphatase, converting PtdIns(3,4,5)P 3 to PtdIns(4,5)P 2 , thereby antagonizing PI(3)K (phosphoinositide 3-kinase) and its established downstream effector pathways 2 . However, much is unclear concerning the mechanisms that regulate PTEN movement to the cell membrane, which is necessary for its activity towards PtdIns(3,4,5)P 3 (refs 3-5). Here we show a requirement for functional motor proteins in the control of PI3K signalling, involving a previously unknown association between PTEN and myosinV. FRET (Förster resonance energy transfer) measurements revealed that PTEN interacts directly with myosinV, which is dependent on PTEN phosphorylation mediated by CK2 and/or GSK3. Inactivation of myosinVtransport function in neurons increased cell size, which, in line with known attributes of PTEN-loss 6, 7 , required PI(3) K and mTor. Our data demonstrate a myosin-based transport mechanism that regulates PTEN function, providing new insights into the signalling networks regulating cell growth.
, the determining cellular machinery remains to be established. We set out to identify proteins involved in regulating the subcellular localization and/or function of PTEN in neurons. Following PTEN immunoprecipitation from brain and liver, SDS-PAGE revealed a prominent brain-specific band with a relative molecular mass of ~205,000 (M r 205K) that was identified as myosinVa by mass spectrometry (Fig. 1a) . The PTEN:myosinVa association was confirmed using co-immunoprecipitation from brain lysates (Fig. 1b) . MyosinVa is a plus-end-directed, processive motor that transports mRNA, proteins and several organelles along actin filaments into the cell periphery, predominantly through interactions with its globular, cargo-binding domain 12 . We co-expressed Flag-tagged myosinVa globular domain (MVag) with GFP-PTEN in HEK293 cells and co-immunoprecipitated PTEN with MVag (Fig. 1d) . To identify the region within PTEN that mediates the association, Flag-MVag was co-expressed with different GFP-tagged PTEN deletion mutants (Fig. 1c, d ). The results indicated that the interaction required aminoacids 354-399 of PTEN, which contain a cluster of phosphorylation sites regulated by CK2 and GSK3 (Fig. 1c, d ) 13, 14 . To test whether the interaction depends on carboxy-terminal PTEN phosphorylation, we used mutant PTEN constructs in which Ser 380, Thr 382 and Thr 383 were mutated to alanines (which cannot be phosphorylated; PTEN AAA) or aspartic acid (which mimics phosphorylation; PTEN DDD) and found that the PTEN:MVag interaction seemed to be greatly reduced in PTEN AAA, whereas PTEN DDD was as efficient in associating with MVag as wild-type PTEN (Fig, 1e) . We then applied inhibitors specific for CK2 (5,6-dichlorobenzimidazole riboside, DRB) and/or GSK3 (CT99021) to GFP-PTEN + Flag-MVag-expressing cells and performed immunoprecipitations as before. The PTEN:MVag association was sensitive to individual inhibition of CK2 or GSK3, and was reduced further when both kinase inhibitors were present (Fig. 1e) . Thus, the PTEN:myosinVa interaction depends on the phosphorylation of residues at the PTEN C terminus, a mechanism demonstrated previously to regulate the binding of PTEN with neutral endopeptidase 15 . To analyse the localization and regulation of the protein:protein interaction in intact cells, we measured FRET between PTEN and myosinVa. We expressed GFP-PTEN and mCherry-MVag in PC12 cells and analysed FRET by fluorescence lifetime imaging microscopy (FLIM) 16 . Data demonstrated reproducible spots in GFP lifetime reduction, indicative of a direct PTEN:MVag interaction, that were confined to small patches in the cell periphery (Fig. 1f) . In agreement with our co-immunoprecipitation experiments, we found that treatment with DRB and/ or CT99021 reduced PTEN:MVag FRET efficiencies (Fig. 1f, g ). Thus, PTEN interacts directly with myosinVa in a spatially regulated manner that is dependent on the activities of CK2 and GSK3.
MyosinVa is highly enriched in the nervous system ( Supplementary  Information, Fig. 1 ), where it localizes within neuronal growth cones and dendritic spines [17] [18] [19] . In humans, mutations in myosinVa cause Griscelli syndrome type 1 and Elejalde syndrome, which are both characterized by hypopigmentation of the skin and hair, as well as prepubescent onset of severe neurological abnormalities, including seizures and mental retardation 20 . Similarly, mice lacking functional myosinVa due to homozygous deletion of dilute lethal Myo5a d-1 (dilute lethal mice) show neurological abnormalities 17 . We used dilute lethal mice to test the possibility that myosinVa mediates PTEN movement towards the membrane. In this case myosinVa deficiencies should phenocopy loss of PTEN, potentially generating neurons in the cerebral cortex and hippocampus with enlarged soma, ectopic processes and increased numbers of synapses 6, 7, 21, 22 . However, gross morphology of neurons in the cortex and the hippocampus at postnatal day (P) 16 was normal in dilute lethal mice ( Supplementary Information, Fig. 2 ). In addition to myosinVa, two other mysosin class members, myosinVb and myosinVc, have been identified 23, 24 and co-immunoprecipitation experiments revealed interactions with PTEN ( Supplementary Information,   Fig. 3 ). MyosinVb, but not myosinVc, is expressed in the developing brain ( Supplementary Information, Fig. 4 ), raising the possibility of functional compensation following loss of myosinVa. Therefore, we exploited the MyosinVa globular domain, which is known to block myosinVa-mediated transport 25 , and, when present in excess, should compete with other myosinVs for interacting with PTEN. IresGFP or MVag-IresGFP was expressed in hippocampal neurons cultured from wild-type mice and dilute lethal littermates at 7 days in vitro (DIV) and neuronal morphology was assessed at 14 DIV. MVag-IresGFP induced a significant increase in neuronal soma size (Fig. 2a, b) , which was inhibited by the PI(3)K inhibitor LY294002 (Fig. 2a, b) . This result provides functional evidence that myosinV regulates PI(3)K signalling, possibly by coordinating membrane transport of PTEN. To test this idea, we forced PTEN to the membrane by myristoylation (myrPTEN), which uncouples myosinV-mediated transport from PTEN function. Expression of myrPTEN inhibited the effect of MVag on soma size (Fig. 2c) . We then tested the effect of the mTor inhibitor rapamycin, an established downstream signalling component of neuronal hypertrophy in PTEN-deficient brains 6 . Rapamycin treatment reduced soma size in IresGFP-and also in MVag-expressing neurons (Fig. 2c) . We also complemented the dominant-negative MVag approach by silencing myosinVb in neurons. We co-transfected hippocampal neurons cultured from wild-type mice and dilute lethal littermates with IresGFP in the presence of unspecific control siRNA or myosinVb-specific siRNA, which resulted in a small, but significant, increase in soma sizes in neurons obtained from dilute lethal mice only ( Supplementary Information,  Fig. 5 ). These data demonstrate that loss of myosinV transport function through overexpression of MVag, as well as through functional inactivation of the two main myosinVs in hippocampal neurons, mimics PTEN deficiency with respect to soma size. Collectively, these results are consistent with a model in which myosinV transport regulates PI(3) K signalling through interaction with PTEN.
To study whether myosinV controls neuronal size in vivo, we injected constructs expressing MVag and GFP, or GFP alone, into the lateral ventricle of embryonic day (E) 13.5 mouse embryos and performed in utero electroporation 26 . After normal embryonic development in vivo for two days, many GFP-expressing neurons adopted morphologies typical for their movement along the radial fibre scaffold, with a leading process extending toward the cortical plate and an axon trailing toward the ventricular zone (Fig. 2d) . MVag expression permitted radial orientation in most neurons, although the calibre of the leading process seemed to be enlarged (Fig. 2d) . Most notably, MVag-expressing neurons showed a significant increase in the size of their somas (Fig. 2d, e) . Thus, functional myosinVs are also essential for the proper control of neuronal size in vivo.
C-terminal PTEN phosphorylation has been shown previously to induce a conformational switch of the protein, keeping the enzyme in a 'closed' formation with decreased membrane localization and biological activity 27, 28 . Our results demonstrating that PTEN binds preferentially with myosinVa when in its phosphorylated state may indicate competition between intramolecular PTEN interaction and an interaction with myosinV. To test this idea, we examined whether the association of a C-terminal fragment of PTEN (PTEN C2 + tail; amino-acids 182-403) with Flag-MVag (Fig. 1d) can be blocked by an amino-terminal fragment of PTEN (PTEN N, amino-acids 1-317; Fig. 3a) . We co-expressed MVag and the GFP-PTEN C2 + tail mutant with increasing levels of PTEN N in HEK293 cells, and co-immunoprecipitated the PTEN tail mutant with myosinVa. Whereas PTEN N failed to interact with MVag (data not shown), increasing levels of PTEN N competed with MVag for the PTEN tail association (Fig. 3b) . Phosphorylation-dependent interactions of the PTEN C-terminal tail have been reported to require a cluster of three positively charged amino acids 15 . We identified two similar clusters with high degree of conservation amongst all myosinV class members (Fig. 3c) , and mutated them individually to uncharged glutamine, asparagine and isoleucine (MVa* RKRαQNI and MVa** KKKαQNI), as described previously 15 . Only the second cluster (KKK) was essential for the association of MVag with PTEN in immunoprecipitation experiments and, significantly, also for increases in soma size of neurons expressing native MVag-IresGFP (Fig. 3d-f) . These experiments indicate that the PTEN:myosinV interaction is based on electrostatic interactions between PTEN and a positively charged region located in the globular domain of myosinV, which is in competition with the closed conformation of PTEN.
We next investigated potential upstream regulators of the PTEN:myosinV interaction and neuronal soma size. We showed that the PTEN:myosinVa interaction is antagonized following inhibition of GSK3 and CK2 (Fig. 1) , which indicates that these kinases may negatively regulate neuronal soma size upstream of PTEN transport. To test this hypothesis, we applied DRB and CT99021 to hippocampal neurons for seven days, before analysis of soma size. Inhibition of CK2 and GSK3 led to soma size increases in IresGFP-expressing neurons, but not in neurons expressing myrPTEN (Fig. 4a) . In mice, neuron-specific overexpression of constitutively active GSK3 decreases brain volume, resulting in microcephaly due to the reduced size of neurons 29 . Correspondingly, we found that somas of hippocampal neurons were significantly smaller following overexpression of the constitutively active GSK3β S9A mutant (Fig. 4a) . In contrast, perturbation of myosinV-transport by co-expressing MVag with GSK3β S9A maintained MVag-enlarged neuronal soma size, which places GSK3 activity upstream of myosinV transport and cell size regulation. To further substantiate this signalling relationship, we co-expressed a . Expression of myrPTEN C124S alone increased neuronal soma size (Fig. 4a) , and we reasoned that in combination with GSK3β S9A , myrPTEN C124S shows unequivocally whether GSK3 operates upstream or downstream of PTEN:myosinV interaction in controlling soma size. The myrPTEN C124S phenotype was dominant (Fig. 4a) , which highlights a requirement for functional PTEN to decrease growth resulting from overactivation of GSK3.
We next assessed whether the evidence for GSK3 controlling neuronal soma size by regulating the PTEN:myosinV interaction could be correlated with the activity of the growth-control signalling machinery. Cell size enlargements caused by PTEN-deficiency require mTor 6 , and correlate with elevated phosphorylation of its effector ribosomal protein S6 (pS6; ref. 7) . Hippocampal neurons maintain robust pS6 signals, which remain unaffected by expression of IresGFP (Fig. 4c) . As expected, rapamycin treatment resulted in decreased pS6-labelling, confirming the specificity of this approach. Similarly, GSK3β S9A expression was accompanied by decreased pS6-labelling, whereas co-expression of GSK3β S9A with MVag antagonised GSK3-induced reduction in pS6 levels (Fig. 4c) . Neurons expressing myrPTEN C124S , or myrPTEN
C124S
in combination with GSK3β S9A showed marked amplification of pS6 in comparison with non-transfected neurons (Fig. 4c) . Collectively, these results establish a causal link between GSK3 as upstream regulator of the PTEN:myosinV interaction and the control of neuronal soma size and mTor signalling. We have demonstrated a transport mechanism controlling PI(3)K signalling and neuronal soma size that involves direct interaction of myosinV with the tumour suppressor PTEN. This interaction is likely to permit a degree of cellular signalling integration, as PTEN associates with myosinV, and antagonizes PI(3)K signalling and functions, when GSK3 is active. Consistent with an established role for PI(3)K in negatively regulating GSK3 itself, our identification of a mechanism by which GSK3 phosphorylation controls PTEN function provides a new possible positive feedback system that operates together with CK2 (Fig. 4b) . Such organization offers a powerful way to amplify or inhibit PI(3)K signalling thresholds required for neurons to respond to extracellular signals involved in determining and maintaining proper neuronal soma size in the brain.
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